Platelet microparticle formation and thrombin generation under high shear effectively suppressed by a monoclonal antibody against GPIbα

Thrombosis and Haemostasis

Volumn 96, Issue 6, 2006, Pages 774-780

  Pontiggia, Luca ^a   Steiner, Beat ^b   Ulrichts, Hans ^c   Deckmyn, Hans ^c   Forestier, Marc ^a   Beer, Jürg H ^a  

^a Kantonsspital Baden   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Antiplatelet agents; High shear; Platelet glycoprotein lb; Platelet microparticles; Thrombin

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; AMINO ACID DERIVATIVE; AMINOPHOSPHOLIPID; CITRATE TRISODIUM; CITRIC ACID; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; EPITOPE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLUCOSE; GLYCOPROTEIN IB ALPHA; LIPOCORTIN 5; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1B 23; PROTEIN INHIBITOR; RISTOCETIN; THROMBIN; TIROFIBAN; VON WILLEBRAND FACTOR;

ANTIBODY LABELING; ANTICOAGULATION; ARTERY OCCLUSION; ARTICLE; CELL FRACTIONATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME INHIBITION; FLOW CYTOMETRY; FORCE; HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SHEAR RATE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; THROMBOCYTOPOIESIS; THROMBOSIS; VISCOMETER;

ANNEXIN A5; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPE MAPPING; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PHOSPHATIDYLSERINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STRESS, MECHANICAL; THROMBIN; TYROSINE; VON WILLEBRAND FACTOR;

EID: 33845371471     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-07-0367     Document Type: Article

References (38)

1. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-3.
2. Nomura S, Uehata S, Saito S, et al. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost 2003; 89: 506-12.
3. Morel O, Hugel B, Jesel L, et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost 2004; 2: 1118-26.
4. Craft JA, Masci PP, Roberts MS, et al. Increased platelet-derived microparticles in the coronary circulation of percutaneous transluminal coronary angioplasty patients. Blood Coagul Fibrinolysis 2004; 15: 475-82.
5. Miyamoto S, Marcinkiewicz C, Edmunds LH, Jr., et al. Measurement of platelet microparticles during cardiopulmonary bypass by means of captured ELISA for GPIIb/IIIa. Thromb Haemost 1998; 80: 225-30.
6. Preston RA, Jy W, Jimenez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003; 41: 211-7.
7. Morel O, Hugel B, Jesel L, et al. Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infaretion in diabetes mellitus. Thromb Haemost 2004; 91: 345-53.
8. Lee YJ, Jy W, Horstman LL, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 1993; 72: 295-304.
9. Andoh A, Tsujikawa T, Hata K, et al. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol 2005; 100: 2042-8.
10. Lee DH, Warkentin TE, Denomme GA, et al. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 1996; 95: 724-31.
11. Miyazaki Y, Nomura S, Miyake T, et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing micropartictes. Blood 1996; 88: 3456-64.
12. Nomura S, Tandon NN, Nakamura T, et al. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-87.
13. Morel O, Toti E Hugel B, et al. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11: 156-64.
14. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003; 1: 1655-62.
15. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004; 10: 171-8.
16. Sims PJ, Wiedmer T, Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-57.
17. Weiss HJ. Scott syndrome: a disorder of platelet coagulant activity. Semi Hematol 1994; 31: 312-9.
18. Goto S, Tamura N, Li M, et al. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J Thromb Haemost 2003; 1: 2022-30.
19. Lincoff AM, Califf RM, Van de Werf F, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. J Am Med Assoc 2002; 288: 2130-5.
20. Haga JH, Slack SM, Jennings LK. Comparison of shear stress-induced platelet microparticle formation and phosphatidylserine expression in presence of alphaIIbbeta3 antagonists. J Cardiovasc Pharmacol 2003; 41: 363-71.
21. Wu D, Meiring M, Kotze HF, et al. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vase Biol 2002; 22: 323-8.
22. Pontiggia L, Steiner B, Beer J. 50% of the thrombin generation under high shear rate is mediated by platelet microparticles and can be inhibited by a monoclonal antibody against GPIb. Blood 2003; 804 a (Abstract 2979).
23. Feng S, Lu X, Kroll MH. Filamin binding to glycoprotein Ibalpha signals talin-directed alphaIIbBeta3 activation. Blood 2005; 106: 115a (Abstract).
24. Genewein U, Haeberli A, Straub P, et al. Rebound after cessation of oral anticoagulant therapy: The biochemical evidence. Brit J Haematol 1996; 92: 479-85.
25. Goding JW Monoclonal Antibodies: Principles and Practice. Production and Application of Monoclonal Antibodies in Cell Biology, Biochemistry and Immunology. 2nd ed. ed. London: Academic Press Limited; 1986.
26. Cauwenberghs N, Vanhoorelbeke K, Vauterin S, et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein lbalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 2001; 98: 652-60.
27. Ulrichts H, Vanhoorelbeke K, Cauwenberghs S, et al. von Willebrand factor but not alpha-thrombin binding to platelet glycoprotein Ibalpha is influenced by the HPA-2 polymorphism. Arterioscler Thromb Vase Biol 2003; 23: 1302-7.
28. Holme PA, Orvim U, Hamers MJ, et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vase Biol 1997; 17: 646-53.
29. Greve B, Beller C, Cassens U, et al. High-grade loss of leukocytes and hematopoietic progenitor cells caused by erythrocyte-lysing procedures for flow cytometric analyses. J Hematother Stem Cell Res 2003; 12: 321-30.
30. Pontiggia L, Lassila R, Pederiva S, et al. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GPIa and GPIIIa. Arterioscler Thromb Vase Biol 2002; 22: 2093 98.
31. Hemker HC, Giesen PL, Ramjee M, et al. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-91.
32. Beguin S, Kumar R, Keularts I, et al. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999; 93: 564-70.
33. Reininger AJ, Heijnen HF, Schumann H, et al. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 2006; 107: 3537-45.
34. Kereiakes DJ, Lorenz T, Young JJ, et al. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis 2001; 12: 123-7.
35. Cauwenberghs N, Meiring M, Vauterin S, et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vase Biol 2000; 20: 1347-53.
36. Gemmell CH, Sefton MV, Yeo EL. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem 1993; 268: 14586-9.
37. Ilveskero S, Lassila R. Abciximab inhibits procoagulant activity but not the release reaction upon collagen- or clot-adherent platelets. J Thromb Haemost 2003; 1: 805-13.
38. Thomas S, Metcalfe P, Goodall AH, et al. Monoclonal antibodies against platelet membrane glycoproteins IIb/IIIa and Ibalpha inhibit platelet dependent thrombin generation by different mechanisms. Thromb Haemost 2000; 84: 98-103.